Skip to main content
. 2018 Apr 20;13(4):e0196040. doi: 10.1371/journal.pone.0196040

Fig 6. Fate of adoptively transferred DiD-BM-MDSC in the tumor and spleen of breast tumor-bearing mice.

Fig 6

A) Representative flow cytometry plots of the CD45.2/DiD-Cy5+ gated population in PyMT-WT tumors from control mice (primary tumor alone; left) and after adoptive transfer of DiD-BM-MDSCs (right) on day 24 as in Fig 5B and 5C) Flow cytometry analysis of CD11b/Ly6C/Ly6G (B) and CD11b/Ly6C subpopulations (C) as a percentage of CD45/Cy5+ cells within the tumor. D) Flow cytometry analysis of mature myeloid populations including granulocytes (CD11b/Ly6G), macrophages and DCs as a percentage of CD45/Cy5+ cells within the tumor. E) Representative flow cytometry plots of the CD45.2/DiD-Cy5+ gated population within the spleen of PyMT-WT tumor-bearing mice (control; left) and after adoptive transfer of DiD-BM-MDSCs (right). F,G) Flow cytometry analysis of CD11b/Ly6C/Ly6G (F) and CD11b/Ly6C subpopulations (G) as a percentage of CD45/Cy5+ cells within the spleen. H) Flow cytometry analysis of mature myeloid populations including granulocytes, macrophages and DCs as a percentage of CD45/Cy5+ cells within the spleen. Data represented as mean ± SEM; n = 6 for all groups.